Cidara Therapeutics Inc (CDTX)
13.43
+0.40
(+3.07%)
USD |
NASDAQ |
Nov 05, 16:00
13.43
0.00 (0.00%)
After-Hours: 20:00
Cidara Therapeutics Enterprise Value: -72.66M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -72.66M |
| November 01, 2024 | -72.24M |
| October 31, 2024 | -72.87M |
| October 30, 2024 | -74.07M |
| October 29, 2024 | -70.13M |
| October 28, 2024 | -76.60M |
| October 25, 2024 | -75.69M |
| October 24, 2024 | -85.82M |
| October 23, 2024 | -84.84M |
| October 22, 2024 | -84.27M |
| October 21, 2024 | -85.40M |
| October 18, 2024 | -85.12M |
| October 17, 2024 | -85.89M |
| October 16, 2024 | -88.78M |
| October 15, 2024 | -92.79M |
| October 14, 2024 | -91.88M |
| October 11, 2024 | -89.69M |
| October 10, 2024 | -90.33M |
| October 09, 2024 | -88.00M |
| October 08, 2024 | -88.99M |
| October 07, 2024 | -86.03M |
| October 04, 2024 | -87.65M |
| October 03, 2024 | -89.06M |
| October 02, 2024 | -90.12M |
| October 01, 2024 | -89.69M |
| Date | Value |
|---|---|
| September 30, 2024 | -88.71M |
| September 27, 2024 | -88.78M |
| September 26, 2024 | -88.43M |
| September 25, 2024 | -88.22M |
| September 24, 2024 | -88.57M |
| September 23, 2024 | -87.86M |
| September 20, 2024 | -85.05M |
| September 19, 2024 | -81.88M |
| September 18, 2024 | -82.59M |
| September 17, 2024 | -82.51M |
| September 16, 2024 | -81.32M |
| September 13, 2024 | -80.33M |
| September 12, 2024 | -84.49M |
| September 11, 2024 | -82.59M |
| September 10, 2024 | -80.26M |
| September 09, 2024 | -82.02M |
| September 06, 2024 | -83.85M |
| September 05, 2024 | -83.08M |
| September 04, 2024 | -84.73M |
| September 03, 2024 | -82.80M |
| August 30, 2024 | -80.68M |
| August 29, 2024 | -73.22M |
| August 28, 2024 | -73.16M |
| August 27, 2024 | -73.08M |
| August 26, 2024 | -73.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-112.92M
Minimum
Jul 11 2024
143.50M
Maximum
Mar 21 2023
38.15M
Average
40.93M
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.24B |
| Arbutus Biopharma Corp | 586.71M |
| GlycoMimetics Inc | 4.052M |
| FibroGen Inc | 6.090M |
| Cue Biopharma Inc | 65.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.21M |
| Revenue (Quarterly) | 0.302M |
| Total Expenses (Quarterly) | 11.40M |
| EPS Diluted (Quarterly) | -19.99 |
| Profit Margin (Quarterly) | -30.20K% |
| Earnings Yield | -188.2% |
| Normalized Earnings Yield | -54.58 |